aibio
Debt Financing ·
Pelthos amends Horizon venture loan, funds Loans E to H and adds Loans I and J
Horizon Technology Finance is collateral agent and a lender on the amended loan. The new Loan I and Loan J commitments run to December 31, 2027.
PTHS Pelthos Therapeutics Inc.
Pelthos Therapeutics (PTHS) news PTHS reverse split, offering and convertible notes news
Latest Pelthos Therapeutics news
- Company Updates
Pelthos stockholders approve 2026 equity plan and elect eight directors
The plan replaces the 2023 Equity Incentive Plan, as amended and restated, and took effect on approval at the September 29, 2026 annual meeting. Grant Thornton LLP was ratified as auditor for 2026.
- Distress
Pelthos Therapeutics says first-quarter 2026 financials can no longer be relied on, will restate
Pelthos Therapeutics said on August 13, 2026 that its first-quarter 2026 financial statements can no longer be relied on. The restatement adds $14.8 million to the accumulated deficit, and the company reports a material weakness in its controls over convertible debt.
- Company Updates
Pelthos CEO to present at Jefferies Global Healthcare Conference on June 4, 2026
Scott Plesha will present and hold one-on-one investor meetings in New York. The company furnished its May 28, 2026 press release and a company presentation.
- Company Updates
Pelthos changes auditor and sets out separation terms for former CFO
Pelthos dismissed CBIZ CPAs P.C. and engaged Grant Thornton LLP for 2026. The filing names Francis Knuettel II, whose separation agreement provides 12 months of base salary, or $430,000.00.
- Company Updates
Pelthos issues first-quarter 2026 results release and posts company presentation
The company furnished a press release summarizing results for the three months ended March 31, 2026, with an update on operations. The 8-K body does not repeat the figures in that release.
- Company Updates
Pelthos CEO to attend investor meetings at Piper Sandler symposium in Boston
Scott Plesha will hold one-on-one investor meetings at the Piper Sandler Spring Biopharma Symposium on April 16, 2026. The company also made a presentation available on its website.
- Mergers
Channel Therapeutics (now Pelthos Therapeutics) closes merger and $50.1 million private placement
The July 1, 2025 closing included a one-for-ten reverse stock split, a name change and royalty sales to Nomis RoyaltyVest, Ligand and Madison Royalty LLC. The shares were to trade as PTHS.
- Mergers
Channel Therapeutics (now Pelthos) sets 10-for-one reverse split ahead of merger
Channel Therapeutics will cut its share count from about 6,485,007 to about 648,501 in a 10-for-one reverse split before its merger with LNHC and a roughly $50 million raise led by Murchinson. The company says the split is meant to help it meet NYSE American initial listing requirements.
What Pelthos Therapeutics does
Pelthos Therapeutics Inc. is a bio-pharmaceutical company committed to commercializing therapeutic products for patients with unmet treatment burdens. It has three FDA approved products in its commercial portfolio: ZELSUVMI, XEPI and XEGLYZE. ZELSUVMI (berdazimer) topical gel, 10.3% is a nitric oxide releasing agent indicated for the topical treatment of molluscum contagiosum in adults and pediatric patients one year of age and older. It was launched in July 2025, shortly after the merger of Channel Therapeutics Corporation and LNHC, Inc. on July 1, 2025. The company also holds a manufacturing facility for the active pharmaceutical ingredient used in ZELSUVMI, the NITRICIL technology platform, and clinical-stage assets that selectively target the sodium ion-channel NaV1.7. During the fourth quarter of 2025 it acquired two additional FDA approved products. On January 12, 2026, the company entered a Venture Loan and Security Agreement with Horizon Technology Finance Corporation for a senior secured term loan of up to $50.0 million, of which $30.0 million was borrowed that day. The proceeds support commercialization, preparation for the launch of the two recently acquired products, working capital and general corporate purposes.
| Product or program | What it is | Stage |
|---|---|---|
| ZELSUVMI (berdazimer) topical gel, 10.3% | Topical nitric oxide releasing agent for molluscum contagiosum | FDA approved; launched July 2025 |
| XEPI | Commercial product; indication not described in the text | FDA approved |
| XEGLYZE | Commercial product; indication not described in the text | FDA approved |
| NaV1.7 assets | Assets selectively targeting the NaV1.7 sodium ion-channel | Clinical-stage |
Pelthos Therapeutics annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $16.8 million | $0 |
| Research and development | $1.2 million | $1.2 million |
| Net income (loss) | -$43.3 million | -$8.0 million |
| Cash from operations | -$22.6 million | -$5.8 million |
| Cash and equivalents | $18.0 million | $513,000 |
Questions about Pelthos Therapeutics
Did Pelthos Therapeutics do a reverse stock split?
Our latest story on this, dated Jul 2, 2025: "Channel Therapeutics (now Pelthos Therapeutics) closes merger and $50.1 million private placement". The story links the filing or release it is based on. Read the story.
Has Pelthos Therapeutics raised money recently?
Our latest story on this, dated Jul 2, 2025: "Channel Therapeutics (now Pelthos Therapeutics) closes merger and $50.1 million private placement". The story links the filing or release it is based on. Read the story.
Has Pelthos Therapeutics sold convertible notes?
Our latest story on this, dated Aug 13, 2026: "Pelthos Therapeutics says first-quarter 2026 financials can no longer be relied on, will restate". The story links the filing or release it is based on. Read the story.
Is Pelthos Therapeutics involved in a merger or acquisition?
Our latest story on this, dated Jul 2, 2025: "Channel Therapeutics (now Pelthos Therapeutics) closes merger and $50.1 million private placement". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Pelthos Therapeutics?
Pelthos Therapeutics Inc. trades under the ticker PTHS on AMEX.
Where is Pelthos Therapeutics listed?
Pelthos Therapeutics Inc. is listed on AMEX.
What is the SEC CIK of Pelthos Therapeutics?
The SEC Central Index Key (CIK) for Pelthos Therapeutics Inc. is 1919246. Its filings are on SEC EDGAR.
How many shares does Pelthos Therapeutics have outstanding?
3,828,469 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-13.
Which country or territory is Pelthos Therapeutics listed under?
Our directory records Pelthos Therapeutics Inc. under United States.
What does Pelthos Therapeutics do?
Our directory classifies Pelthos Therapeutics Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Pelthos Therapeutics?
The ISIN recorded for Pelthos Therapeutics Inc. is US1711262048.
Does aibio.space cover Pelthos Therapeutics?
aibio.space lists Pelthos Therapeutics Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Pelthos Therapeutics incorporated?
SEC records list its state or country of incorporation as NV.
What does Pelthos Therapeutics develop?
Pelthos Therapeutics Inc. is a bio-pharmaceutical company committed to commercializing therapeutic products for patients with unmet treatment burdens. It has three FDA approved products in its commercial portfolio: ZELSUVMI, XEPI and XEGLYZE.
What is ZELSUVMI (berdazimer) topical gel, 10.3% from Pelthos Therapeutics?
ZELSUVMI (berdazimer) topical gel, 10.3%: Topical nitric oxide releasing agent for molluscum contagiosum Stage: FDA approved; launched July 2025.
Investor discussion: Pelthos Therapeutics
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Mergers
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,2.03,3.02,3.03,5.02,5.03,5.07,7.01,9.01). Source
- Legal
Said earlier financial statements should no longer be relied on. SEC Form 8-K (Items 4.02). Source
- Legal
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,5.02,9.01). Source
- Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
- Financings
Reported a financing. SEC Form 8-K (Items 1.01,2.03,3.02,7.01,9.01). Source
- Financings
Reported a financing. SEC Form 8-K (Items 1.01,2.03,3.02,8.01,9.01). Source
- Mergers
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,2.01,2.03,3.02,3.03,5.01,5.02,5.03,8.01,9.01). Source
- Legal
Reported a change of independent auditor. SEC Form 8-K (Items 1.01,3.02,4.01,5.07,7.01,8.01,9.01). Source
- Mergers
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,2.03,3.03,5.02,5.03,9.01). Source
Stock chart
SEC filings and registration
- SEC name
- Pelthos Therapeutics Inc.
- CIK
- 1919246
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) (2836)
- US tickers
- PTHS (NYSE)
- State or country of incorporation
- NV
- Fiscal year ends
- December 31
- Filer category
- <br>Emerging growth company
- Business address
- 4020 STIRRUP CREEK DRIVE, DURHAM, NC, 27703
- Phone
- 919-908-2422
- Shares outstanding
- 3,828,469 as of 2026-08-10 (10-Q filed 2026-08-13)
- Former names
- Channel Therapeutics Corp; Chromocell Therapeutics Corp
Recent filings
Listing details
- Company
- Pelthos Therapeutics Inc.
- Ticker
- PTHS
- Listing
- AMEX
- Country or territory
- United States
- Business scope
- Pharmaceuticals: Major
- ISIN
- US1711262048
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction